All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @keepingrosieaccountable on TikTok · 17s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @keepingrosieaccountable's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00I'll live my day at noon

Rosie's 49-pound Mounjaro weight loss: what's realistic?

rosie

TikTok creator

44.9K viewsWatch on TikTok

Quick answer

Tirzepatide is a dual GLP-1/GIP receptor agonist that led to 22.5% average weight loss in the SURMOUNT-1 trial. The medication works by slowing gastric emptying and reducing appetite through hormonal pathways.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded TirzepatideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Rosie's 49-pound Mounjaro weight loss: what's realistic?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Tirzepatide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Rosie's 49-pound Mounjaro weight loss: what's realistic?" from rosie. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tirzepatide is a dual GLP-1/GIP receptor agonist that led to 22.

The reason this review is not generic is the source wording and the canonical claim label "glp1 progress is progress 3 and a half stone down there s a lon." In this clip, the useful excerpt is: "I'll live my day at noon" That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

91% of trial participants lost at least 5% of their body weight on tirzepatide
People who land here are usually comparing the Compounded Tirzepatide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Tirzepatide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Tirzepatide is a dual GLP-1/GIP receptor agonist that led to 22.

FormBlends verdict

Compounded Tirzepatide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Tirzepatide is a dual GLP-1/GIP receptor agonist that led to 22.5% average weight loss in the SURMOUNT-1 trial. The medication works by slowing gastric emptying and reducing appetite through hormonal pathways.
  • SURMOUNT-1 trial showed 22.5% average weight loss with 15mg tirzepatide over 72 weeks
  • 91% of trial participants lost at least 5% of their body weight on tirzepatide

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Compounded Tirzepatide

What You'll Learn

  • SURMOUNT-1 trial showed 22.5% average weight loss with 15mg tirzepatide over 72 weeks
  • 91% of trial participants lost at least 5% of their body weight on tirzepatide
  • PCOS patients may see enhanced benefits due to improved insulin sensitivity from GLP-1 medications
  • Common side effects include nausea (29% of users) and vomiting (13% of users) in clinical trials
  • About 7% of participants dropped out of trials due to side effects
  • Monthly costs range from $900-1,200 without insurance coverage
  • Long-term use is typically required to maintain weight loss results

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What does this TikTok video claim?

@keepingrosieaccountable shares that she's lost 3.5 stone (49 pounds) using Mounjaro for weight loss while managing PCOS. She frames this as progress on a longer weight loss journey.

The video is refreshingly straightforward. No wild promises about miracle cures or dramatic before-and-after transformations. Rosie simply documents her weight loss progress and acknowledges she has more work ahead.

Her mention of PCOS is relevant since this condition affects 6-12% of women of reproductive age and often makes weight management more challenging due to insulin resistance and hormonal imbalances.

Is losing 49 pounds on tirzepatide realistic?

Yes, this amount of weight loss matches clinical trial data for tirzepatide (Mounjaro's active ingredient). The SURMOUNT-1 trial found average weight loss of 22.5% with the 15mg dose over 72 weeks.

For context, that's roughly 45-67 pounds for someone starting at 200-300 pounds. Rosie's 49-pound loss fits well within this range, though we don't know her timeline or starting weight.

The trial data shows most weight loss occurs in the first 36-52 weeks, with the medication working through GLP-1 and GIP receptor activation to slow gastric emptying and reduce appetite. About 91% of participants lost at least 5% of their body weight.

Does PCOS affect how well Mounjaro works?

Women with PCOS may actually see enhanced benefits from GLP-1 medications like tirzepatide. A 2023 study in Diabetes Care found that liraglutide improved insulin sensitivity and menstrual regularity in PCOS patients.

PCOS creates insulin resistance that makes traditional weight loss methods less effective. GLP-1 receptor agonists directly address this insulin resistance while also reducing appetite.

However, no large-scale trials have specifically tested tirzepatide in PCOS populations. The evidence comes from smaller studies with other drugs in this class, so we're extrapolating somewhat.

What's missing from this success story?

Rosie doesn't mention timeline, which matters enormously for evaluating her results. Losing 49 pounds over six months is very different from losing it over two years.

She also doesn't discuss side effects, which affect most people starting tirzepatide. The SURMOUNT-1 trial reported nausea in 29% of participants and vomiting in 13%. About 7% dropped out due to side effects.

The "long way to go" comment suggests she's targeting additional significant weight loss. While tirzepatide can support this, the medication works best alongside lifestyle changes that she doesn't detail here.

Should you expect similar results?

Rosie's results are encouraging but not guaranteed for everyone. Individual responses to tirzepatide vary widely based on genetics, adherence, starting weight, and lifestyle factors.

The medication requires weekly injections and typically costs $900-1,200 monthly without insurance coverage. Most people need to stay on it long-term to maintain weight loss.

If you have PCOS and struggle with weight management, tirzepatide represents a legitimate medical option worth discussing with your doctor. Just don't expect identical results to what you see on social media.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

rosie · TikTok creator

44.9K views on this video

Progress is progress. 3 and a half stone down, there’s a long way to go but I’m proud of where I’m at so far ✨#weightlossjouney #mounjaro #mounjarojourney #pcos #mounjaroupdate

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about surmount-1 trial showed 22.5% average weight loss with 15mg tirzepatide?

SURMOUNT-1 trial showed 22.5% average weight loss with 15mg tirzepatide over 72 weeks

What does the video say about 91% of trial participants lost at least 5% of their?

91% of trial participants lost at least 5% of their body weight on tirzepatide

What does the video say about pcos patients may see enhanced benefits due to improved insulin?

PCOS patients may see enhanced benefits due to improved insulin sensitivity from GLP-1 medications

What does the video say about common side effects include nausea (29% of users)?

Common side effects include nausea (29% of users) and vomiting (13% of users) in clinical trials

What does the video say about about 7% of participants dropped out of trials due to?

About 7% of participants dropped out of trials due to side effects

What does the video say about monthly costs range from $900-1,200 without insurance coverage?

Monthly costs range from $900-1,200 without insurance coverage

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by rosie, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.